UMN Pharma Inc. - Product Pipeline Review - 2012

Summary

“UMN Pharma Inc. - Product Pipeline Review - 2012” provides data on the UMN Pharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, UMN Pharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from UMN Pharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- UMN Pharma Inc. - Brief UMN Pharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of UMN Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of UMN Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the UMN Pharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate UMN Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of UMN Pharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the UMN Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with UMN Pharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of UMN Pharma Inc. and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
UMN Pharma Inc. Snapshot 5
UMN Pharma Inc. Overview 5
Key Information 5
Key Facts 5
UMN Pharma Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
UMN Pharma Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
UMN Pharma Inc. – Pipeline Products Glance 10
UMN Pharma Inc. – Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
UMN Pharma Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
UMN Pharma Inc. – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
UMN Pharma Inc. – Drug Profiles 13
FluBlok 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
PanBlok 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
UMN-2003 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
UMN Pharma Inc. – Pipeline Products by Route of Administration 19
UMN Pharma Inc. – Recent Pipeline Updates 20
UMN Pharma Inc. - Dormant Projects 21
Supratek Pharma Inc. – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Financial Deals Landscape 23
UMN Pharma Inc., Deals Summary 23
UMN Pharma Inc., Pharmaceuticals & Healthcare, Deal Details 25
Venture Financing 25
UMN Pharma Secures $19 Million In Series C Financing 25
UMN Pharma Secures $7.5 Million In Series B-2 Financing Round 29
Partnerships 32
UMN Pharma Enters Into Co-Development Agreement With API 32
UMN Pharma Forms Joint Venture With IHI 33
Licensing Agreements 34
Crucell And DSM Biologics Enter Into Licensing Agreement With UMN Pharma 34
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok 35
Astellas Pharma Enters Into Licensing Agreement With UMN Pharma 37
Protein Sciences Enters Into Licensing Agreement With UMN Pharma 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
UMN Pharma Inc., Key Information 5
UMN Pharma Inc., Key Facts 5
UMN Pharma Inc. – Pipeline by Indication, 2012 7
UMN Pharma Inc. – Pipeline by Stage of Development, 2012 8
UMN Pharma Inc. – Monotherapy Products in Pipeline, 2012 9
UMN Pharma Inc. – Phase III, 2012 10
UMN Pharma Inc. – Phase II, 2012 11
UMN Pharma Inc. – Pre-Clinical, 2012 12
UMN Pharma Inc. – Pipeline By Route of Administration, 2012 19
UMN Pharma Inc. – Recent Pipeline Updates, 2012 20
UMN Pharma Inc. - Dormant Developmental Projects,2012 21
UMN Pharma Inc., Other Locations 22
UMN Pharma Inc., Deals Summary 23
UMN Pharma Secures $19 Million In Series C Financing 25
UMN Pharma Secures $7.5 Million In Series B-2 Financing Round 29
UMN Pharma Enters Into Co-Development Agreement With API 32
UMN Pharma Forms Joint Venture With IHI 33
Crucell And DSM Biologics Enter Into Licensing Agreement With UMN Pharma 34
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok 35
Astellas Pharma Enters Into Licensing Agreement With UMN Pharma 37
Protein Sciences Enters Into Licensing Agreement With UMN Pharma 38

List of Figures
UMN Pharma Inc. – Pipeline by Indication, 2012 7
UMN Pharma Inc. – Pipeline by Stage of Development, 2012 8
UMN Pharma Inc. – Monotherapy Products in Pipeline, 2012 9